- Home
- RSSS vs BOLD Comparison
RSSS vs BOLD Comparison
Compare RSSS & BOLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RSSS | BOLD |
|---|---|---|
| Founded | 2006 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Business Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 97.3M | 26.2M |
| IPO Year | N/A | 2024 |
Fundamental Metrics
Financial Performance| Metric | RSSS | BOLD |
|---|---|---|
| Price | $2.91 | $1.21 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | ★ $5.00 | $4.00 |
| AVG Volume (30 Days) | 74.9K | ★ 144.6K |
| Earning Date | 02-12-2026 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.04 | N/A |
| Revenue | ★ $49,325,684.00 | N/A |
| Revenue This Year | $4.92 | N/A |
| Revenue Next Year | $7.09 | N/A |
| P/E Ratio | $72.26 | ★ N/A |
| Revenue Growth | ★ 5.83 | N/A |
| 52 Week Low | $2.32 | $1.00 |
| 52 Week High | $4.24 | $3.12 |
Technical Indicators
Market Signals| Indicator | RSSS | BOLD |
|---|---|---|
| Relative Strength Index (RSI) | 47.53 | 51.20 |
| Support Level | $2.82 | $1.17 |
| Resistance Level | $3.05 | $1.37 |
| Average True Range (ATR) | 0.14 | 0.08 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 41.54 | 34.62 |
Price Performance
Historical ComparisonAbout RSSS Research Solutions Inc
Research Solutions Inc is a holding company. The company provides vertical software-as-a-service ("SaaS") and artificial intelligence ("AI") solutions, providing software and related services to help research-intensive organizations simplify the research process, save time, and money. The company operates in a single segment, which derives its revenue from subscription fees from its cloud-based SaaS Platforms and transactional service fees for the electronic delivery of single articles. The company generates the majority of its revenue from the Transactions. Geographically, the company generates the majority of its revenue from the United States, followed by Europe.
About BOLD Boundless Bio Inc.
Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.